Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.8%

1 terminated/withdrawn out of 26 trials

Success Rate

95.0%

+8.5% vs industry average

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

26%

5 of 19 completed trials have results

Key Signals

2 recruiting5 with results

Enrollment Performance

Analytics

Phase 1
19(79.2%)
Phase 2
4(16.7%)
Phase 3
1(4.2%)
24Total
Phase 1(19)
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT00253435Phase 2Completed

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Role: lead

NCT00093353Phase 1Completed

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Role: lead

NCT00509353Phase 1Completed

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Role: lead

NCT00295919Phase 1Completed

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

Role: lead

NCT00083135Phase 1Completed

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Role: lead

NCT00646230Phase 1Completed

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Role: lead

NCT06450041Phase 2Recruiting

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Role: lead

NCT01587300Recruiting

Neuroblastoma Biology Study

Role: lead

NCT02868268Active Not Recruiting

Neuroblastoma Precision Trial

Role: lead

NCT02573896Phase 1Active Not Recruiting

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Role: lead

NCT02298348Phase 1Active Not Recruiting

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Role: lead

NCT07261241Phase 2Not Yet Recruiting

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

Role: lead

NCT03107988Phase 1Completed

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Role: lead

NCT03332667Phase 1Completed

MIBG With Dinutuximab +/- Vorinostat

Role: lead

NCT04724369Phase 3Completed

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Role: collaborator

NCT02030964Phase 1Completed

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

Role: lead

NCT00002730Phase 1Completed

Chemotherapy in Treating Children With Neuroblastoma

Role: lead

NCT00885326Phase 1Completed

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Role: lead

NCT00084422Phase 1Completed

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Role: lead

NCT01019850Phase 1Completed

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Role: lead